Mesenchymal Stem Cells and Subclinical Rejection (Measure)

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

M.E. J. Reinders, Leiden University Medical Center

ClinicalTrials.gov Identifier:

NCT00734396

First received: August 13, 2008

Last updated: January 4, 2013

Last verified: January 2013

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	December 2012
Primary Completion Date:	March 2012 (Final data collection date for primary outcome measure)

No publications provided by Leiden University Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Reinders ME, de Fijter JW, Roelofs H, Bajema IM, de Vries DK, Schaapherder AF, Claas FH, van Miert PP, Roelen DL, van Kooten C, Fibbe WE, Rabelink TJ. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med. 2013 Feb;2(2):107-11. doi: 10.5966/sctm.2012-0114. Epub 2013 Jan 24.

To Top